Specify a stock or a cryptocurrency in the search bar to get a summary
Mind Medicine Inc
MNMDMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Address: One World Trade Center, New York, NY, United States, 10007
Analytics
WallStreet Target Price
26.63 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MNMD
Dividend Analytics MNMD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MNMD
Stock Valuation MNMD
Financials MNMD
Results | 2019 | Dynamics |